DIP Ep 677: The Extremely Clutch USPSTF Podcast (Part 1)

Source / episode info

• Episode: 677
• Title: DIP Ep 677: The Extremely Clutch USPSTF Podcast (Part 1)
• Published: 2026-10-24
• Source: DIP Ep 677: The Extremely Clutch USPSTF Podcast (Part 1)

One-liner

Part 1 of the Clutch USPSTF Guide covers core Grade A/B evidence-based screening recommendations: updated starting ages for colorectal cancer (45) and breast cancer (40), cervical cytology vs hrHPV intervals, lung cancer low-dose CT criteria, and AAA ultrasound indications.

High-yield summary

• Colorectal Cancer (CRC) Screening (Grade A: Ages 45–75): The recommended starting age was reduced from 50 to 45 for average-risk individuals. Acceptable modalities and intervals: (1) Colonoscopy every 10 years (gold standard; diagnostic and therapeutic); (2) Annual Fecal Immunochemical Test (FIT); (3) Stool DNA-FIT (Cologuard) every 3 years; (4) Flexible sigmoidoscopy every 5 years (or every 10 years + annual FIT); (5) CT colonography every 5 years. Any positive non-colonoscopy stool test requires prompt diagnostic colonoscopy. Screening between ages 76–85 is selective (Grade C); discontinue after age 85. High-risk exceptions: 1st-degree relative diagnosed < 60 yr -> start at age 40 or 10 years before youngest relative diagnosis, colonoscopy every 5 years. Lynch syndrome -> start at age 20–25, colonoscopy q1–2y. FAP -> start at age 10–12, annual flexible sigmoidoscopy.
• Breast Cancer Screening (Grade B: Ages 40–74): In 2024, USPSTF lowered the biennial screening mammography recommendation to begin at age 40 (previously 50) through age 74. Modality: Screening mammography every 2 years. Clinical breast exams and breast self-examinations are NOT recommended by USPSTF (insufficient evidence / false positives). Women with BRCA1/2 mutations or history of chest radiation therapy at age 10–30 require annual screening MRI + mammography starting at age 25–30.
• Cervical Cancer Screening (Grade A: Ages 21–65): Begins at age 21 regardless of sexual debut or HPV vaccination status! Ages 21–29: Cervical cytology (Pap smear) alone every 3 years. Do NOT screen with HPV testing in this age group due to high transient HPV prevalence. Ages 30–65: Three acceptable options: (1) Cytology alone every 3 years; (2) High-risk HPV (hrHPV) testing alone every 5 years; or (3) Cytology + hrHPV co-testing every 5 years. Discontinue screening after age 65 if adequate prior negative screening (3 consecutive negative Paps or 2 consecutive negative co-tests within past 10 years, with most recent within 5 years). Discontinue screening in women who had total hysterectomy with cervix removal for benign disease.
• Lung Cancer & Abdominal Aortic Aneurysm (AAA) Screening: Lung cancer (Grade B): Annual low-dose computed tomography (LDCT) in adults aged 50–80 who have a >= 20 pack-year smoking history AND currently smoke or have quit within the past 15 years. Discontinue screening once the person has not smoked for 15 years or develops a health problem limiting life expectancy. Abdominal Aortic Aneurysm (Grade B): One-time abdominal duplex ultrasound in men aged 65–75 who have EVER smoked (defined as >= 100 lifetime cigarettes). Grade C in men 65–75 who never smoked; Grade D (recommend against) in women who never smoked.
• Metabolic & Cardiovascular Screening: Prediabetes & Type 2 Diabetes (Grade B): Screen all asymptomatic adults aged 35–70 who are overweight or obese (BMI >= 25; >= 23 in Asian Americans) using fasting plasma glucose, HbA1c, or 2-hour oral glucose tolerance test every 3 years. Statin Primary Prevention (Grade B): Low-to-moderate intensity statin in adults aged 40–75 with NO prior CVD, 1+ cardiovascular risk factor (dyslipidemia, diabetes, HTN, smoking), AND calculated 10-year ASCVD risk >= 10% (Grade C if ASCVD 7.5–10%). Osteoporosis (Grade B): Screening with dual-energy X-ray absorptiometry (DEXA) in women aged >= 65, or postmenopausal women < 65 with elevated fracture risk score (FRAX). Aspirin for CVD prevention (Grade C): USPSTF advises against initiating low-dose aspirin in adults >= 60 for primary prevention due to bleeding risk.

Learning objectives

• Differentiate the starting ages and intervals for USPSTF Grade A/B cancer screenings (CRC at 45, Breast at 40, Cervix at 21).
• Apply the revised 20 pack-year and age 50–80 criteria for annual low-dose CT lung cancer screening.
• Determine when to order a one-time screening ultrasound for abdominal aortic aneurysm (AAA) based on sex, age, and smoking history.
• Choose between Pap smear alone versus Pap/HPV co-testing based on patient age (21–29 vs 30–65).
• Calculate indications for primary prevention statin therapy using ASCVD risk estimation and traditional risk factors.

Board exam buzzwords

Rapid review table

Board-speak -> diagnosis

Management pearls

• A "smoker" for AAA screening is defined as having smoked at least 100 cigarettes in an entire lifetime. Even if a 68-year-old man quit 40 years ago, if he smoked 5 packs total in college, he qualifies for the one-time abdominal ultrasound!
• In colorectal cancer screening, if a patient has a first-degree relative diagnosed with CRC before age 60, screening begins at age 40 or 10 years earlier than the relative diagnosis age (whichever is earlier), and colonoscopy is repeated every 5 years (not 10 years).
• Discontinuing Pap smears at age 65 requires documentation of adequate prior negative screening: 3 consecutive negative cytology results or 2 consecutive negative co-tests within the past 10 years, with the most recent performed within 5 years.

Don't miss

OMM / COMLEX integration

• Viscerosomatic screening reflexes for the colon: Ascending and transverse colon sympathetic innervation arises from T10–T11 (superior mesenteric ganglion); descending colon, sigmoid, and rectum arise from T12–L2 (inferior mesenteric ganglion). Persistent palpatory paraspinal hypertonicity at T10–L2 warrants clinical evaluation.
• Pelvic diaphragm and sacral mobility: The pelvic diaphragm (levator ani, coccygeus) supports pelvic viscera and is innervated by S2–S4. Somatic dysfunction of the sacrum (sacral torsion or bilateral sacral flexion) affects autonomic and lymphatic drainage of the rectum, bladder, and reproductive organs. Pelvic diaphragm release facilitates lymphatic return.